Skip to main content
Signal8

CERO THERAPEUTICS HOLDINGS, INC. (CERO) Form 424B3 — Jun 26, 2026

$CEROForm 424B3Filed Jun 26, 2026, 4:09 PM ET0001213900-26-072609Original filing

Cero Therapeutics entered into an amended and restated promissory note with SRX Health Solutions for up to $1.4 million. The note carries a 10% interest rate and matures on May 28, 2027. The note is convertible into common stock at a price equal to the lower of $0.05 or 80% of the average of the five lowest trading prices in the 20 days prior to conversion. This structure provides significant downside protection for the lender but poses substantial dilution risk to existing shareholders.

Key figures

Debt Amount
$1,413,600
Interest Rate
10%
Maturity Date
May 28, 2027
Shares Offered
729,596,950
Funded Amount
$1,413,600
Conversion Price Mechanism
Lesser of $0.05 or 80% of average of 5 lowest trading prices in 20 days prior to conversion

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.